Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model

Vaccine

Volumn 26, Issue 16, 2008, Pages 1999-2009

  Cazorla, Silvia I ^a,b,c   Frank, Fernanda M ^a,b   Becker, Pablo D ^c   Corral, Ricardo S ^d   Guzmán, Carlos A ^c   Malchiodi, Emilio L ^a,b  

^a Instituto de Estudios de la Inmunidad Humoral   (Argentina)

^b Facultad de Medicina   (Argentina)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Chagas disease; MALP 2; Trypanosoma cruzi

Indexed keywords

CRUZIPAIN; GAMMA INTERFERON; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; RECOMBINANT CRUZIPAIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EXPERIMENTAL INFECTION; FEMALE; IMMUNIZATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; MUSCLE INJURY; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; TRYPOMASTIGOTE; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHAGAS DISEASE; CYSTEINE ENDOPEPTIDASES; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; INTERFERON TYPE II; MICE; MICE, INBRED C3H; MUSCLE, SKELETAL; MYOCARDIUM; OLIGOPEPTIDES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SPLEEN; TOLL-LIKE RECEPTOR 2; TRYPANOSOMA CRUZI; VACCINATION; VACCINES, SYNTHETIC;

EID: 40849124047     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.011     Document Type: Article

References (41)

1. Tropical disease research. Twelfth programme report of the UNDP/World Bank/WHO special programme for research and training in tropical disease (TDR). Geneva, Switzerland: World Health Organization; 1999.
2. Moncayo A. Progress towards interruption of transmission of Chagas disease. Mem Inst Oswaldo Cruz 94 Suppl 1 (1999) 401-404
3. Andrade Z.A. Pathogenesis of Chagas' disease. Res Immunol 142 2 (1991) 126-129
4. Bestetti R.B., and Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 60 2 (1997) 187-193
5. Rassi Jr. A., Rassi A., and Little W.C. Chagas' heart disease. Clin Cardiol 23 12 (2000) 883-889
6. +) T lymphocytes. Infect Immun 57 7 (1989) 2246-2248
7. + T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J Immunol 144 2 (1990) 717-724
8. Tarleton R.L., Sun J., Zhang L., and Postan M. Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease. Infect Immun 62 5 (1994) 1820-1829
9. Rottenberg M.E., Riarte A., Sporrong L., Altcheh J., Petray P., Ruiz A.M., et al. Outcome of infection with different strains of Trypanosoma cruzi in mice lacking CD4 and/or CD8. Immunol Lett 45 1/2 (1995) 53-60
10. Tarleton R.L., Zhang L., and Downs M.O. "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proc Natl Acad Sci USA 94 8 (1997) 3932-3937
11. Hoft D.F., Lynch R.G., and Kirchhoff L.V. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi. J Immunol 151 12 (1993) 7038-7047
12. Humphrey J.S., McCormick T.S., and Rowland E.C. Parasite antigen-induced IFN-γ and IL-4 production by cells from pathopermissive and pathoresistant strains of mice infected with Trypanosoma cruzi. J Parasitol 83 3 (1997) 533-536
13. Kumar S., and Tarleton R.L. Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J Immunol 166 7 (2001) 4596-4603
14. Munoz-Fernandez M.A., Fernandez M.A., and Fresno M. Activation of human macrophages for the killing of intracellular Trypanosoma cruzi by TNF-alpha and IFN-gamma through a nitric oxide-dependent mechanism. Immunol Lett 33 1 (1992) 35-40
15. Kierszenbaum F., and Howard J.G. Mechanisms of resistance against experimental Trypanosoma cruzi infection: the importance of antibodies and antibody-forming capacity in the Biozzi high and low responder mice. J Immunol 116 5 (1976) 1208-1211
16. Lima-Martins M.V., Sanchez G.A., Krettli A.U., and Brener Z. Antibody-dependent cell cytotoxicity against Trypanosoma cruzi is only mediated by protective antibodies. Parasite Immunol 7 4 (1985) 367-376
17. Sepulveda P., Hontebeyrie M., Liegeard P., Mascilli A., and Norris K.A. DNA-based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect Immun 68 9 (2000) 4986-4991
18. Hoft D.F., Farrar P.L., Kratz-Owens K., and Shaffer D. Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses. Infect Immun 64 9 (1996) 3800-3810
19. Brandariz S., Schijman A., Vigliano C., Arteman P., Viotti R., Beldjord C., et al. Detection of parasite DNA in Chagas' heart disease. Lancet 346 8986 (1995) 1370-1371
20. Tarleton R.L., and Zhang L. Chagas disease etiology: autoimmunity or parasite persistence?. Parasitol Today 15 3 (1999) 94-99
21. + dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci USA 103 28 (2006) 10729-10734
22. Frank F.M., Petray P.B., Cazorla S.I., Munoz M.C., Corral R.S., and Malchiodi E.L. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 22 1 (2003) 77-86
23. Schnapp A.R., Eickhoff C.S., Sizemore D., Curtiss III R., and Hoft D.F. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun 70 9 (2002) 5065-5074
24. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
25. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186 10 (1997) 1623-1631
26. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 6813 (2000) 740-745
27. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32 10 (2002) 2857-2865
28. Borsutzky S., Kretschmer K., Becker P.D., Muhlradt P.F., Kirschning C.J., Weiss S., et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 174 10 (2005) 6308-6313
29. Chiari E., and Camargo E.P. Culturing and cloning of Trypanosoma cruzi. In: Morel C.M. (Ed). Genes and antigens of parasites (1984), Fundação Oswaldo Cruz, Rio de Janeiro 23-26
30. Mühlradt P.F., Kieß M., Meyer H., Süßmuth R., and Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185 11 (1997) 1951-1958
31. Campetella O., Henriksson J., Aslund L., Frasch A.C., Pettersson U., and Cazzulo J.J. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. Mol Biochem Parasitol 50 2 (1992) 225-234
32. Martinez J., and Cazzulo J.J. Anomalous electrophoretic behaviour of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi in relation to its apparent molecular mass. FEMS Microbiol Lett 74 2/3 (1992) 225-229
33. Berasain P., Carmona C., Frangione B., Cazzulo J.J., and Goni F. Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 130 1 (2003) 23-29
34. Cazzulo J.J., Stoka V., and Turk V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr Pharm Des 7 12 (2001) 1143-1156
35. Stempin C., Giordanengo L., Gea S., and Cerban F. Alternative activation and increase of Trypanosoma cruzi survival in murine macrophages stimulated by cruzipain, a parasite antigen. J Leukoc Biol 72 4 (2002) 727-734
36. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24 12 (2006) 2049-2056
37. Dennis V.A., Jefferson A., Singh S.R., Ganapamo F., and Philipp M.T. Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3. Infect Immun 74 10 (2006) 5780-5789
38. Rajasingh J., Bord E., Luedemann C., Asai J., Hamada H., Thorne T., et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J 20 12 (2006) 2112-2114
39. Tekiel V.S., Mirkin G.A., and Gonzalez Cappa S.M. Chagas' disease: reactivity against homologous tissues induced by different strains of Trypanosoma cruzi. Parasitology 115 Pt 5 (1997) 495-502
40. de Souza A.P., Olivieri B.P., de Castro S.L., and Araújo-Jorge T.C. Enzymatic markers of heart lesion in mice infected with Trypanosoma cruzi and submitted to benznidazole chemotherapy. Parasitol Res 86 10 (2000) 800-808
41. Cazorla S.I., Frank F.M., Becker P., Sartori M.J., Corral R.S., Malchiodi E.L., et al. Oral vaccination with Salmonella as cruzipain-DNA delivery system confers protective immunity against T. cruzi. Infect Immun 76 1 (2008) 324-333